NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date (Ascending) | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
24979-0715-44 | 24979-0715 | Sorafenib | Sorafenib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF | Oral | Dec. 1, 2022 | In Use | |
51990-0201-06 | 51990-0201 | Sorafenib | Sorafenib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, RET/PTC,CRAF, BRAF | Oral | Dec. 1, 2022 | In Use | |
51990-0201-12 | 51990-0201 | Sorafenib | Sorafenib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, RET/PTC,CRAF, BRAF | Oral | Dec. 1, 2022 | In Use | |
43826-0066-04 | 43826-0066 | Sorafenib | Sorafenib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF | Oral | Dec. 1, 2022 | In Use | |
00904-7266-61 | 00904-7266 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 2, 2022 | In Use | |
50419-0393-03 | 50419-0393 | LAROTRECTINIB | VITRAKVI | 20.0 mg/mL | Chemotherapy | Tyrosine Kinase Inhibitor | TRK | OROPHARYNGEAL | Dec. 6, 2022 | In Use | |
16729-0250-03 | 16729-0250 | Bendamustine hydrochloride | Bendamustine hydrochloride | 25.0 mg/5mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Dec. 7, 2022 | In Use | |
16729-0251-05 | 16729-0251 | Bendamustine hydrochloride | Bendamustine hydrochloride | 100.0 mg/20mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Dec. 7, 2022 | In Use | |
50090-6259-00 | 50090-6259 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 7, 2022 | In Use | |
71225-0120-01 | 71225-0120 | BENDAMUSTINE HYDROCHLORIDE | VIVIMUSTA | 25.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Dec. 7, 2022 | In Use | |
80739-0812-12 | 80739-0812 | Adagrasib | KRAZATI | 200.0 mg/1 | Immunotherapy | RAS Inhibitor | KRAS G12C | Oral | Dec. 12, 2022 | In Use | |
80739-0812-18 | 80739-0812 | Adagrasib | KRAZATI | 200.0 mg/1 | Immunotherapy | RAS Inhibitor | KRAS G12C | Oral | Dec. 12, 2022 | In Use | |
63629-9530-01 | 63629-9530 | Doxorubicin hydrochloride | Doxorubicin hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Dec. 12, 2022 | April 30, 2024 | In Use |
71205-0729-10 | 71205-0729 | PREDNISONE | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 12, 2022 | In Use | |
71205-0729-14 | 71205-0729 | PREDNISONE | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 12, 2022 | In Use | |
71205-0729-20 | 71205-0729 | PREDNISONE | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 12, 2022 | In Use | |
71205-0729-21 | 71205-0729 | PREDNISONE | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 12, 2022 | In Use | |
71205-0729-30 | 71205-0729 | PREDNISONE | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 12, 2022 | In Use | |
71205-0729-60 | 71205-0729 | PREDNISONE | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 12, 2022 | In Use | |
71205-0729-63 | 71205-0729 | PREDNISONE | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 12, 2022 | In Use | |
71205-0729-90 | 71205-0729 | PREDNISONE | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 12, 2022 | In Use | |
71288-0145-10 | 71288-0145 | Pemetrexed disodium | Pemetrexed | 100.0 mg/4.2mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Dec. 13, 2022 | In Use | |
71288-0146-50 | 71288-0146 | Pemetrexed disodium | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Dec. 13, 2022 | In Use | |
71288-0147-50 | 71288-0147 | Pemetrexed disodium | Pemetrexed | 750.0 mg/30mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Dec. 13, 2022 | In Use | |
71288-0148-51 | 71288-0148 | Pemetrexed disodium | Pemetrexed | 1.0 g/40mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Dec. 13, 2022 | In Use |
Found 10,000 results in 5 milliseconds — Export these results